Fibroblast growth factor 23 inhibits extrarenal synthesis of 1,25-dihydroxyvitamin D in human monocytes


  • Justine Bacchetta,

    1. UCLA Orthopaedic Hospital, Department of Orthopaedic Surgery, Orthopedic Hospital Research Center, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA, USA
    2. Department of Pediatrics, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA, USA
    Search for more papers by this author
  • Jessica L Sea,

    1. UCLA Orthopaedic Hospital, Department of Orthopaedic Surgery, Orthopedic Hospital Research Center, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA, USA
    Search for more papers by this author
  • Rene F Chun,

    1. UCLA Orthopaedic Hospital, Department of Orthopaedic Surgery, Orthopedic Hospital Research Center, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA, USA
    Search for more papers by this author
  • Thomas S Lisse,

    1. UCLA Orthopaedic Hospital, Department of Orthopaedic Surgery, Orthopedic Hospital Research Center, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA, USA
    Search for more papers by this author
  • Katherine Wesseling-Perry,

    1. Department of Pediatrics, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA, USA
    Search for more papers by this author
  • Barbara Gales,

    1. Department of Pediatrics, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA, USA
    Search for more papers by this author
  • John S Adams,

    1. UCLA Orthopaedic Hospital, Department of Orthopaedic Surgery, Orthopedic Hospital Research Center, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA, USA
    Search for more papers by this author
  • Isidro B Salusky,

    1. Department of Pediatrics, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA, USA
    Search for more papers by this author
  • Martin Hewison

    Corresponding author
    1. UCLA Orthopaedic Hospital, Department of Orthopaedic Surgery, Orthopedic Hospital Research Center, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA, USA
    • UCLA Orthopaedic Hospital Department of Orthopaedic Surgery, 615 Charles E. Young Drive South, Room 410D, Los Angeles, CA 90095-7358, USA.
    Search for more papers by this author


Vitamin D is a potent stimulator of monocyte innate immunity, and this effect is mediated via intracrine conversion of 25-hydroxyvitamin D (25OHD) to 1,25-dihydroxyvitamin D (1,25(OH)2D). In the kidney, synthesis of 1,25(OH)2D is suppressed by fibroblast growth factor 23 (FGF23), via transcriptional suppression of the vitamin D-activating enzyme 1α-hydroxylase (CYP27B1). We hypothesized that FGF23 also suppresses CYP27B1 in monocytes, with concomitant effects on intracrine responses to 1,25(OH)2D. Healthy donor peripheral blood mononuclear cell monocytes (PBMCm) and peritoneal dialysate monocyte (PDm) effluent from kidney disease patients were assessed at baseline to confirm the presence of mRNA for FGF23 receptors (FGFRs), with Klotho and FGFR1 being more strongly expressed than FGFR2/3/4 in both cell types. Immunohistochemistry showed coexpression of Klotho and FGFR1 in PBMCm and PDm, with this effect being enhanced following treatment with FGF23 in PBMCm but not PDm. Treatment with FGF23 activated mitogen-activated protein kinase (MAPK) and protein kinase B (Akt) pathways in PBMCm, demonstrating functional FGFR signaling in these cells. FGF23 treatment of PBMCm and PDm decreased expression of mRNA for CYP27B1. In PBMCm this was associated with downregulation of 25OHD to 1,25(OH)2D metabolism, and concomitant suppression of intracrine induced 24-hydroxylase (CYP24A1) and antibacterial cathelicidin (LL37). FGF23 suppression of CYP27B1 was particularly pronounced in PBMCm treated with interleukin-15 to stimulate synthesis of 1,25(OH)2D. These data indicate that FGF23 can inhibit extra-renal expression of CYP27B1 and subsequent intracrine responses to 1,25(OH)2D in two different human monocyte models. Elevated expression of FGF23 may therefore play a crucial role in defining immune responses to vitamin D and this, in turn, may be a key determinant of infection in patients with chronic kidney disease (CKD). © 2013 American Society for Bone and Mineral Research


Fibroblast growth factor 23 (FGF23) is a protein synthesized by osteocytes and osteoblasts that plays a key role in the “bone-parathyroid-kidney” axis and the regulation of phosphate/calcium/vitamin D metabolism.1–3 FGF23 acts mainly as a phosphaturic factor, inhibiting the expression of type IIa sodium-phosphate co-transporters on the apical membrane of proximal tubular cells, thus leading to inhibition of phosphate reabsorption.4 However, FGF23 also suppresses renal synthesis of the active form of vitamin D, 1,25-dihydroxyvitamin D (1,25(OH)2D) by inhibiting expression of the enzyme 25-hydroxyvitamin D-1α-hydroxylase (CYP27B1) while stimulating the catabolic enzyme vitamin D-24-hydroxylase (CYP24A1).4 FGF23 null mice present with a premature aging phenotype as well as severe growth retardation, abnormal skeletogenesis, vascular and soft tissue calcification, hyperphosphatemia, and increased renal expression of CYP27B1.5 The importance of CYP27B1 as a target for FGF23 is further illustrated by the abrogation of FGF23-knockout skeletal and biochemical abnormalities in FGF23/CYP27B1 double-knockout mice.6, 7

In addition to its effects on mineral and skeletal homeostasis, vitamin D can also act as a potent modulator of immune function.8, 9 In particular, active 1,25(OH)2D can enhance innate immune handling of bacteria via the induction of antibacterial proteins such as cathelicidin (LL37) and β-defensin 2.10, 11 Cells such as monocytes expressing both CYP27B1 and the nuclear vitamin D receptor (VDR) are able to achieve this by localized conversion of 25OHD to 1,25(OH)2D and subsequent VDR-mediated transactivation of antibacterial proteins.12, 13 This intracrine mode of action is enhanced by a variety of immunomodulatory factors, notably following the recognition of pathogen-associated molecular patterns by pattern-recognition receptors.12, 13 Monocyte synthesis of 1,25(OH)2D and associated induction of antibacterial activity can also be enhanced by cytokines such as interleukin-15 (IL-15),14 and interferon γ (IFNγ).15 Conversely, other cytokines such as IL-4 suppress monocyte accumulation of 1,25(OH)2D by enhancing its catabolism via the enzyme 24-hydroxylase (CYP24A1), and thereby inhibit intracrine induction of antibacterial activity in these cells.15 These observations highlight the pivotal importance of vitamin D metabolism in mediating innate immune responses to infection, and underline the potential immune impact of factors that are able to regulate this metabolism. In the current study, we sought to determine whether FGF23 can contribute to this immune regulation of vitamin D metabolism.

In humans, aberrant expression of FGF23 was initially linked to hypophosphatemic rickets,16 but current data suggest that this is far more complex, and includes a role for FGF23 in oncogenic osteomalacia.17 In chronic kidney disease (CKD), elevated serum levels of FGF23 are detectable at early stages of the disease, prior to dysregulation of serum phosphate and parathyroid hormone (PTH).18, 19 In this setting, FGF23 levels have a prognostic value, with higher levels of serum FGF23 being associated with poorer health outcomes.20–23 Although this appears to be a result, at least in part, of vascular and atherogenic effects of FGF23,24, 25 infection is also a key cause of mortality in CKD patients. Aside from the increased risk of infection due to immunosuppressive therapies in CKD patients undergoing kidney transplantation,26 CKD itself is a state of acquired immune deficiency.27 The incidence of bacterial infections in CKD dialysis patients is higher than in the general population28, 29 and infections are the second leading cause of death in such patients. The immune dysfunction observed in CKD patients, such as impaired polymorphonuclear cell apoptosis,30 has been attributed to many different factors, including iron overload, uremic toxins, and dialysis.27 To date, there have been no published studies of FGF23 and immune function, although some reports of FGF23-null mice have described atrophy of the thymus, spleen, and lymph nodes, and decreased capacity for T cell proliferation.6 In the current study we explored a possible role for FGF23 as a mediator of immune dysfunction via its effects on vitamin D metabolism in monocytes.

Materials and Methods

Isolation and initial treatment of peripheral blood mononuclear cells from healthy donors

Ficoll-isolated peripheral blood mononuclear cells (PBMCs) derived from anonymous healthy donors (screened in accordance with standard transfusion medicine protocols) were obtained from the Center for AIDS Research Virology Core/BSL3 Facility (supported by NIH award AI-28697 and by the UCLA AIDS Institute and the UCLA Council of Bioscience Resources, Los Angeles, CA, USA). PBMC monocytes (PBMCm) were enriched by adherence by incubating 5 × 106 PBMCs per well in 12-well plates for 2 hours in Roswell Park Memorial Institute medium (RPMI) (Invitrogen, Carlsbad, CA, USA) with 1% human serum (HS) (Human AB serum; Omega Scientific, Tarzana, CA, USA).

Isolation of monocytes from peritoneal dialysate effluents by iterative centrifugation

Samples of overnight dwell dialysates were collected from patients undergoing peritoneal dialysis as approved by the UCLA Human Subject Protection Committee, with consent forms being obtained from all parents/patients. Dialysate samples were decanted into 500-mL sterile centrifuge tubes, and then centrifuged at 1200g for 10 minutes at room temperature. Supernatants were discarded and cell pellets were combined and re-centrifuged using the same parameters. After again discarding supernatants, viable cells were counted by hemocytometer following staining with Trypan blue. After a third centrifugation the remaining cells were used in vitro for isolation of peritoneal dialysate monocytes (PDm). PDm were selected by adherence by incubating 5 × 106 PD cells per well in 12-well plates for 12 hours in RPMI with 1% HS. All samples were obtained from patients with no evidence of peritonitis.

Culture and treatment of PBMCm and PDm

PBMCm and PDm were cultured at 37°C in 5% CO2 in 12-well plastic cell culture plates using medium containing RPMI 1640, 10% HS, and granulocyte-macrophage colony stimulating factor (GM-CSF) 10 IU/mL (PeproTechInc, Rocky Hood, NJ, USA) for various time periods (6 or 24 hours). Treatments were carried out using recombinant human FGF23 (100 ng/mL, 2604-FG; R&D Systems, Minneapolis, MN, USA), recombinant human IL-15 (200 ng/mL) (247-IL; R&D Systems) or both in comparison to vehicle-treated cells (PBS 1×). The pan fibroblast growth factor receptor (FGFR) inhibitor PD173074 (250 nM) (Sigma Aldrich, St Louis, MO, USA) was used 1 hour before treating cells with FGF23, with control cells receiving DMSO as vehicle. At the end of incubation periods cells were either lysed with RNAzol and frozen at –80°C or processed for Western blot analyses. All culture conditions were carried out in duplicate for RT-PCR analyses.

Extraction of RNA and reverse transcription

After lysing cells PBMCm or PDm with RNAzol, RNA was extracted using chloroform, isopropanol, ethanol, and glycogen, as described.13 After resuspending the resulting RNA in RNase-free water, aliquots (300 ng) were reverse-transcribed as recommended by the manufacturer (SuperScript III Reverse Transcriptase; Invitrogen) as described.13

Quantitative real-time RT-PCR amplification of cDNAs

Expression of mRNAs for VDR, CYP27B1, CYP24A1, LL37, fibroblast growth factor receptor (FGFR)1, FGFR2, FGFR3, FGFR4, Klotho, and tumor necrosis factor α (TNF-α) was quantified using a Stratagene MX3005P device using PBMCm or PDm, as recommended by the manufacturer and as described.13 Approximately 7.5 ng of cDNA was used per reaction. All reactions were normalized by multiplex analysis with the housekeeping 18S rRNA gene (Applied Biosystems, Foster City, CA, USA). Data were obtained as threshold cycle (Ct) values, corresponding to the cycle number at which logarithmic PCR plots cross a calculated threshold line, and were further used to determine the change in Ct values (ΔCt), corresponding to the difference between the Ct of the target gene and the Ct of the housekeeping 18S rRNA gene. PCR amplification of target gene cDNA was conducted using TaqMan human gene expression assays, as described.13 The probes and primer kits used for each gene were as follows: Hs00172113-m1 for VDR, Hs00168017-m1 for CYP27B1, Hs00167999-m1 for CYP24A1, Hs00189038-m1 for LL37, Hs00915134-g1 for FGFR1, Hs01552926-m1 for FGFR2, Hs00179829-m1 for FGFR3, Hs01106908-m1 for FGFR4, Hs00183100-m1 for Klotho, and Hs00174128-m1 for TNFα (Applied Biosystems). All reactions were amplified under the following conditions: 95°C for 10 minutes followed by 40 cycles of 95°C for 30 seconds, 55°C for 1 minute, and 72°C for 1 minute. Reactions were initially expressed as mean ± SD ΔCt values and values for fold-change relative to vehicle-treated cells were determined using the equation 2−ΔCt.

Western blot analyses

For Western blot analysis of FGFR-mediated MAPK and Akt phosphorylation pathways in PBMCm, preliminary experiments showed that optimal expression of phosphorylated MAPK (pMAPK) and Akt (pAkt) was achieved after serum-starvation (0.1% HS) of these cells for 1 and 2 hours, respectively. During this serum starvation period, cells were treated with vehicle or an FGFR inhibitor (FGFRi, 250 nM), and then treated for a further 1 hour with either vehicle, FGF23 (100 ng/mL), FGFRi (250 nM), or FGF23 in combination with FGFRi. At the end of this treatment period, cells were treated with protein lysis buffer (NP40 Cell Lysis Buffer; Invitrogen, Camarillo, CA, USA), the proteinase inhibitor phenylmethylsulfonyl fluoride (PMSF), a proteinase inhibitor cocktail (P8340, 10 µL per mL of NP40; Sigma Aldrich, St. Louis, MO, USA) and phosphatase inhibitor cocktail (P5726, 10 µL per mL of NP40; Sigma Aldrich), and centrifuged at 4°C at 5000g for 20 minutes. Supernatants were then collected and stored at −20°C. Equal amounts of lysate protein were separated by electrophoresis using 10% SDS-PAGE gels with a biotinylated protein ladder (7727; Cell Signaling Technology, Danvers, MA, USA). Resulting blots were incubated for 24 hours with primary antibodies directed against total MAPK (p44/42 Erk1/2) (dilution 1/1000), phosphoMAPK (p44/42 Erk1/2) (dilution 1/800), total Akt (1/1000) and phospho-Akt (1/400) (all Cell Signaling Technology, Danvers, MA, USA; catalog numbers 9102, 9101, 4691, and 4060, respectively). A horseradish peroxidase (HRP) system with an enhanced chemiluminescence (ECL) system was then used for the incubation of secondary antibodies (1 hour, dilution 1/2000) and image development (Phototype-HRP Western blot detection system anti-rabbit 7074, anti-mouse 7076, anti-biotin 7075, and 20× LumiGlo Reagent/20× Peroxide 7003; Cell Signaling Technology). Western blot analyses were quantified using ImageJ software (NIH, Bethesda, MD, USA).

Immunofluorescence analyses

PBMCm or PDm were seeded at 2 × 106 per well in a four-well glass slide (Lab Tek II Chamber Slide System; NalgeNuncInc, Naperville, IL, USA), and cultured in the same medium and with the same reagents described above. After an initial fixation in 500 µL per well of paraformaldehyde (4%) for 10 minutes, slides were subject to the following: three washes with PBS 1×; incubation with 500 µL of a mixture of PBS 1× and Tween 0.2% for 10 minutes; three washes with PBS 1×; incubation with 500 µL of a mixture of PBS 1× and dry milk 5% for 30 minutes; three washes with PBS 1×; incubation for 1 hour in 300 µL of a mixture of PBS 1×, bovine serum albumin, and the following primary antibodies: FGFR1 (Flg-C-15-sc-121, 1/100; Santa Cruz Biotechnologies, Inc., Santa Cruz, CA, USA) and Klotho (246, 1/100, a kind gift from Dr. Jeffrey Lavigne; Immutopics, Inc., San Clemente, CA, USA). After three washes with PBS 1×, slides were then incubated with secondary antibodies labeled with Alexa 488 and 594 (anti-goat and anti-rabbit; Invitrogen, Camarillo, CA, USA) for 1 hour, washed three times with PBS 1×. Nuclear staining was carried out using 100 µL of 4′,6-diamidino-2-phenylindole dihydrochloride (DAPI; Sigma-Aldrich) (1/10 000 for 5 minutes). Slides were then fixed with mounting media (Prolong Gold Antifade Reagent, P36930; Invitrogen) and stored at 4°C in the dark. Imaging was then carried out using a 60× lens, with the Nikon NIS Elements software.

Analysis of 25OHD metabolism by PBMCm

The effects of FGF23 on synthesis of 1,25(OH)2D and 24,25-dihydroxyvitamin D (24,25(OH)2D) by PBMCm were assessed by quantifying the metabolism of radiolabeled 25OHD as described.31 Briefly, aliquots of cells were incubated with radiolabeled 3H-25OHD substrate (300,000 cpm, 155Ci/mmol; Perkin Elmer, Waltham, MA, USA) for 6 hours in serum-free culture medium. The resulting mix of 3H-vitamin D metabolites was then extracted from the total cell lipids using initial C18 Sep-pak purification (Waters, Milford, MA, USA) and subsequent HPLC (ZorbaxSil column; Agilent, Santa Clara, CA, USA) separation of 1α-hydroxylated and 24-hydroxylated vitamin D metabolites. 3H-25OHD, 3H-24,25(OH)2D and 3H-1,25(OH)2D was quantified by Beta-Ram in-line scintillation counting (Lablogic, Brandon, FL, USA). Data were reported as femtomoles of vitamin D metabolites produced/hour/106 cells from n = 5 separate cell preparations.


Data are presented as mean ± SEM for fold-changes in mRNA expression and HPLC metabolism data, and as mean ± SD for raw RT-PCR data and Western blot analyses. Experimental means were compared statistically using an unpaired Student's t test. Where indicated, multifactorial data involving FGF23 and co-treatments were compared using one way analysis of variance (ANOVA) with the Holm-Sidak method used as a post hoc multiple comparison procedure. Statistical analyses were carried out using raw ΔCt values and fold-changes. Spearman correlation test was used for bivariate analyses.


Expression and regulation of FGFRs in PBMCm

To assess the ability of monocytes to respond to FGF23, PBMCm were analyzed for expression of different FGFRs and the FGFR co-receptor Klotho. As shown in Table 1, basal, untreated cultures of PBMCm expressed mRNA for FGFR1, -2 and -4 as well as Klotho but did not express FGFR3. Although expression of FGFR1 was much higher than other FGFRs or Klotho, analysis of PBMCm from multiple donors showed a strong positive correlation between mRNA for FGFR1 and Klotho (Fig. 1A), CYP27B1 (Supplemental Fig. 1A), and the antibacterial factor LL37 (Supplemental Fig. 1B), but not CYP24A1 (Supplemental Fig. 1C). Treatment of PBMCm with FGF23 (100 ng/mL) suppressed expression of mRNA for Klotho at 6 hours, and FGFR1 at 24 hours (Fig. 1B). Immunofluorescence confirmed that PBMCm express protein for Klotho and FGFR1, with coincident expression of the two proteins in some but not all untreated PBMCm cells (Fig. 1C). Treatment with FGF23 (24 hours) enhanced expression of protein for Klotho and FGFR1 in some but not all cells (Fig. 1C).

Table 1. Expression of mRNA for FGFRs and Klotho in PBMCm
 ΔCt (mean ± SD)Fold change to relative to FGFR1
  1. Expression of mRNA for FGFR1, -2, -3, -4, and Klotho in baseline (untreated) PBMCm. Data are shown as mean ΔCt PCR amplification values ± SD, normalized to expression of the housekeeping gene 18S rRNA (central column), and fold-change in mRNA expression relative to the most highly expressed mRNA (FGFR1) (right column), both n = 35 donor batches of PBMCm.

  2. FGFR = fibroblast growth factor receptor; PBMCm = peripheral blood mononuclear cell–derived monocytes; ΔCt = threshold cycle change.

FGFR111.32 ± 1.561
FGFR222.15 ± 2.070.00055
FGFR424.34 ± 1.900.00012
Klotho21.12 ± 2.040.00112
Figure 1.

Expression and regulation of fibroblast growth factor receptors (FGFR) and Klotho in PBMCm. (A) Baseline expression of FGFR1 mRNA in PBMCm correlates with Klotho mRNA (Spearman correlation coefficient of 0.585, p < 0.001, 35 different batches of PBMCs). (B) Effect of FGF23 (100 ng/mL) on expression of mRNA Klotho, FGFR1, FGFR2, and FGFR4 in PBMCm in vitro was assessed after 6 hours (black bars) and 24 hours (gray bars) treatments. Data show combined results using PBMCm from healthy donors at 6 hours (eight donors) and 24 hours (five donors). (C) Effect of FGF23 (100 ng/mL, 24 hours) on expression of Klotho (red), FGFR-1 (green), and nuclear DAPI (blue) protein in PBMCm, as determined by immunofluorescence microscopy. Merged immunofluorescence shows coexpression of FGFR1 and Klotho in PBMCm.

Effects of FGF23 on FGFR signaling in PBMCm

Having demonstrated expression of FGFR1 and Klotho in PBMCm, we next sought to characterize the signaling response of these receptors following exposure to FGF23. Initial analyses showed that optimal expression of phosphorylated MAPK (pMAPK) and Akt (pAkt) was achieved after serum-starvation (1% HS) pretreatment for 1 and 2 hours respectively (Fig. 2A). Expression of pMAPK and pAkt was induced after treatment with FGF23 (100 ng/mL) for 30 minutes (Fig. 2A, B), with no further induction of pMAPK or pAkt after 60 or 120 minutes (data not shown). Pretreatment of PBMCm with the FGFR inhibitor PD173074 (FGFRi, 250 nM) for 1 hour suppressed the activation of these two phosphorylation pathways following treatment with FGF23 (Fig. 2A, B).

Figure 2.

FGF23 modulates FGFR signaling in PBMCm. (A) Effect of FGF23 (100 ng/mL) on MAPK and Akt signaling in PBMCm. Data are shown as representative Western blots showing expression of protein for: total MAPK; phosphoMAPK (pMAPK); total Akt; phosphoAkt (pAkt). PBMC were pretreated under conditions of serum deprivation (0.1% human serum) for either 1 hour or 2 hours with or without an FGFR inhibitor (FGFRi, 250 nM), and then treated with or without vehicle or FGF23 (100 ng/mL) for a further 1 hour. (B) Quantification of changes in expression of pMAPK (1 hour pretreatment, left panel) and pAkt (2 hour pretreatment, right panel) expression normalized to total MAPK and Akt, respectively. Data were determined using ImageJ software and represent mean ± SD values for n = 3 separate donor PBMCm cultures. **statistically different from vehicle-treated PBMCm, p < 0.01; ##statistically different from FGF23-treated PBMCm, p < 0.01.

FGF23 decreases expression of CYP27B1 and intracrine synthesis of 1,25(OH)2D in PBMCm

Treatment with FGF23 (100 ng/mL) decreased expression of mRNA for CYP27B1 in PBMCm after 6 and 24 hours (Fig. 3A). This effect was paralleled by decreased expression of the 1,25(OH)2D-target genes CYP24A1 (6 and 24 hours) and LL37 (24 hours) (Fig. 3A). PBMCm pretreated with IL-15 (48 hours) showed a twofold increase in CYP27B1 mRNA relative to vehicle-treated cells, but this effect was inhibited by subsequent exposure to FGF23 (100 ng/mL, 24 hours) (Fig. 3B). HPLC analysis of vitamin D metabolism in five different batches of PBMCm showed that treatment with FGF23 inhibited monocyte synthesis of active 1,25(OH)2D (Fig. 3C, D). Vehicle-treated cells (9.9 ± 2.9 fmol/hour/106 cells), and cells treated with FGF23 alone (10.9 ± 4.2 fmol/hour/106 cells) showed similar levels of 1,25(OH)2D production. However, cells treated with IL-15 showed a significant increase in synthesis of 1,25(OH)2D (76.3 ± 12.1 fmol/hour/106 cells), with this effect being significantly inhibited by co-treatment with FGF23 (42.5 ± 9.5 fmol/hour/106 cells). Synthesis of 24,25(OH)2D was undetectable under each culture condition (Fig. 3D).

Figure 3.

FGF23 suppresses expression and activity of CYP27B1 in PBMCm. (A) Effect of FGF23 (100 ng/mL) at 6 hours (black bars) and 24 hours (gray bars) on expression of mRNA for CYP27B1, CYP24A1, VDR, LL37, and tumor necrosis factor α (TNFα) in PBMCm. Data shown are mean ± SEM fold changes in mRNA expression relative to vehicle-treated cells for PBMCm from eight different healthy donors. (B) Effect of FGF23 (100 ng/mL, 24 hours) alone or following preactivation of cells with interleukin-15 (IL-15, 200 ng/mL, 48 hours) on CYP27B1 mRNA expression in PBMCm. Data are shown as fold change in CYP27B1 mRNA relative to vehicle-treated cells for PBMCm from three different healthy donors. (C) Effect of vehicle (V) or FGF23 (100 ng/mL, 24 hours) alone or following preactivation of cells with IL-15 (200 ng/mL, 48 hours) on conversion of 25OHD to 1,25(OH)2D in PBMCm. Data are shown as femtomoles 1,25(OH)2D synthesized/hour/106 cells for PBMCm from n = 5 different healthy donors. (D) Effect of FGF23 (100 ng/mL, 24 hours) alone or after preactivation of cells with IL-15 (200 ng/mL, 48 hours) on conversion of 25OHD to 1,25(OH)2D in PBMCm. Data are shown as representative HLPC analyses for each treatment. *statistically different compared to vehicle, p < 0.05; #statistically different from IL-15–treated cells, p < 0.05.

FGF23-mediated suppression of intracrine vitamin D activity in monocytes isolated from peritoneal dialysate effluent

Monocytes isolated from peritoneal effluents of patients undergoing maintenance continuous peritoneal dialysis (PDm), showed a fivefold higher basal expression of FGFR1 and eightfold higher levels of CYP24A1 (Table 2). Treatment of PDm in vitro with FGF23 (100 ng/mL) resulted in similar responses to those observed with PBMCm: expression of mRNA for CYP27B1, CYP24A1, and Klotho was decreased after 6 hours of treatment with FGF23 (Fig. 4A); by contrast, expression of LL37 was unaffected by treatment with FGF23, although baseline expression of LL37 in PDm cells was 0.12 relative to that observed in PBMCm (Table 2). At the protein level, coexpression of Klotho and FGFR1 was observed in basal and FGF23-treated cultures of PDm (Fig. 4B).

Table 2. Relative Expression of Vitamin D- and FGF23-Related Genes in PDm Versus PBMCm
 ΔCtPDm (mean ± SD)ΔCtPBMCm (mean ± SD)Fold-change relative to PBMCm
  • Baseline expression of mRNAs for CYP27B1, CYP24A1, VDR, cathelicidin (LL37), Klotho, and FGFR1 in PDm was compared to the expression of these genes in PBMCm. Data in left-hand and central columns are shown as raw mRNA expression (ΔCt) data (mean ± SD) for the gene of interest normalized to expression of the housekeeping 18S rRNA gene. Data in the right-hand column are shown as fold-change mRNA expression for PDm relative to the equivalent gene in PBMCm. Combined results from 14 batches of PD cells and 45 batches of PBMCm.

  • PDm = peritoneal dialysate monocytes; PBMCm = peripheral blood mononuclear cell–derived monocytes; ΔCt = threshold cycle change; VDR = vitamin D receptor; LL37 = cathelicidin; FGFR1 = fibroblast growth factor receptor 1.

  • *

    Statistically different from PBMCm, p < 0.05.

CYP27B112.09 ± 2.2111.90 ± 2.940.88
CYP24A117.59 ± 2.9020.58 ± 3.117.96*
VDR12.47 ± 3.6014.14 ± 4.043.17
LL3722.38 ± 3.5819.38 ± 3.050.12*
Klotho19.23 ± 2.0320.57 ± 2.422.53
FGFR19.57 ± 3.0611.78 ± 2.054.63*
Figure 4.

FGF23 suppresses expression of CYP27B1 in monocytes from peritoneal dialysates. (A) Effect of FGF23 (100 ng/mL, 6 hours) on expression of mRNA for CYP27B1, CYP24A1, Klotho, and FGFR1 in peritoneal dialysate monocytes (PDm). Data are shown as mean ± SEM fold change in mRNA expression relative to vehicle-treated cells for PDm from n = 7 different donors. (B) Immunofluorescence analysis of protein for Klotho (green), FGFR-1 (red), and nuclear DAPI (blue) in PDm. Merged immunofluorescence shows coexpression of FGFR1 and Klotho in PDm. *statistically different from vehicle-treated PDm, p < 0.05.


Vitamin D is a potent regulator of innate32 and adaptive immunity,8 with these effects being highly dependent on local conversion of 25OHD to 1,25(OH)2D by monocytes12, 13 and/or dendritic cells (DCs).33, 34 This intracrine activation of vitamin D within the immune system is sensitively induced by immunogenic stimuli,12, 13 or exposure to cytokines such as IL-1514 or IFNγ.15 Although induction of CYP27B1 appears to be important for normal immune function, overactivity of the enzyme has been linked to pathological conditions such as granulomatous disease and associated hypercalcemia.35 Specific mechanisms that may help to prevent CYP27B1 overactivity following a pathogenic challenge include induction of the vitamin D catabolic enzyme CYP24A1.36 In monocytes, as classically observed in the kidney, 1,25(OH)2D itself potently induces expression of CYP24A1 with this effect being enhanced following Toll-like receptor (TLR) activation.12 However, induction of monocyte vitamin D catabolism is not restricted to 1,25(OH)2D-mediated self-regulation. Recent studies have shown that the cytokine IL-4 suppresses intracrine-induced antibacterial responses to 25OHD through enhanced monocyte 24-hydroxylase activity.15 This mechanism suggests that T cells from the adaptive immune system are able to attenuate synthesis of 1,25(OH)2D by monocytes and/or DCs indirectly via induction of 24-hydroxylase vitamin D catabolism. What is less clear is whether CYP27B1 itself is a target for suppression of monocyte 1,25(OH)2D production. In classical vitamin D endocrinology, renal expression of CYP27B1 is inhibited by FGF23 as a counterpoint to the stimulatory actions of PTH.5 The aim of the current study was to determine whether similar FGF23-mediated regulation of CYP27B1 occurs in an extrarenal setting.

The significant decrease of CYP27B1 expression and activity in FGF23-treated monocytes is consistent with the classical actions of FGF23 on renal synthesis of 1,25(OH)2D. However, our data contrast previous studies describing FGF23-mediated upregulation of CYP27B1 in another extrarenal tissue, namely parathyroid cells.37 The precise physiological basis for these different extrarenal activities of FGF23 is unclear, and effects on parathyroid cells may simply represent an alternative mechanism to enhance vitamin D-mediated control of PTH secretion. In classical vitamin D endocrinology, FGF23-mediated suppression of CYP27B1 is accompanied by increased expression of the catabolic enzyme CYP24A1, with the latter acting to further attenuate renal production of 1,25(OH)2D.4, 38, 39 It was therefore interesting to note that monocyte expression of CYP24A1 is suppressed by FGF23 in parallel with its effects on CYP27B1. The most likely explanation is that, in the absence of cytokines such as IL-4, monocyte expression of CYP24A1 is primarily dependent on local synthesis of 1,25(OH)2D. Because synthesis of 1,25(OH)2D is decreased in the presence of FGF23, expression of CYP24A1 will also decline. Renal expression of CYP24A1 is also stimulated by 1,25(OH)2D but it is known to be sensitive to other endocrine factors such as PTH, which has been reported to regulate both transcription of CYP24A140 and stability of the resulting mRNA.41 Thus, FGF23-mediated regulation of CYP24A1 in the kidney may be entirely different to its effects in monocytes.

Previous studies have reported expression of FGFR1 in interstitial inflammatory renal monocytes,42 but, to the best of our knowledge, our data provide the first evidence for combined expression of FGFR1 and Klotho in monocytes outside the kidney. In other cell types FGF23 has been shown to bind to multiple FGFRs.38, 43–45 For example, recent studies have shown that FGFR3 and FGFR4 are the most likely receptors for FGF23-mediated regulation of serum 1,25(OH)2D levels.44 Nevertheless, the relatively high levels of FGFR1 in PBMCm and PDm suggest that this is the likely principal target for FGF23 in these cells, with Klotho acting as a co-receptor. Irrespective of the precise receptor isoform involved in mediating inhibition of monocyte CYP27B1, the MAPK and Akt phosphorylation pathways that appear to be activated by FGF23 in monocytes have also been linked to FGF23 responses in other cell types.38, 43, 46, 47 This contrasts with recent studies of FGF23 responses in cardiomyocytes, which were Klotho-and MAPK/Akt-independent.45 Functional interplay between FGF23 and vitamin D in monocytes is supported by other observations from our study. First, both PBMC and PD monocytes show decreased expression of Klotho and FGFR1 after treatment with FGF23. Second, at baseline, there is a strong positive relationship between mRNA expression for Klotho and FGFR1, but also between FGFR1 and CYP27B1 and between FGFR1 and LL37. Finally, the PD cells, from patients chronically exposed to high circulating levels of FGF23,48 have a lower baseline expression of LL37 relative to PBMCm. This provides a potential explanation for the lack of significant suppression of LL37 expression in PDm treated with FGF23 in vitro.

Decreased monocyte function following exposure to FGF23 may influence several disease scenarios. The key role of FGF23 in phosphate physiology was first highlighted in pediatric autosomal dominant hypophosphatemic rickets (ADHR).16 Unlike CKD and end-stage renal disease,48, 49 ADHR involves only moderately increased circulating levels of FGF23, and is not known to present with the same infections observed in CKD, except for a tendency to dental abscesses,50 and some reported pulmonary infections.51 The latter may be due to effects of increased FGF23, but may also involve thoracic deformations induced by rickets or direct effects of vitamin D deficiency.52, 53 However, elevated FGF23 may influence other aspects of vitamin D physiology. Increased levels of vitamin D have been associated with improved survival and cardiovascular status in CKD patients,54 whereas vitamin D treatments have also been linked to decreased risk of cardiovascular deaths among dialysis patients.55, 56 Conversely, high circulating levels of FGF23 are strongly associated with risk of mortality and cardiovascular disease in patients with CKD,23 and we propose that this may be due, at least in part, to FGF23-mediated dysregulation of extrarenal vitamin D function. The precise mechanisms linking FGF23, vitamin D, and cardiovascular disease are as yet unclear but could involve suppression of the intracrine immunomodulatory actions of 25OHD in disease-affected cells. This may include monocytes and DCs, but endothelial cells are also known to express CYP27B1, with the latter being induced by inflammatory stimuli.57

The most immediate clinical implication of the data presented in this study is the potential link between elevated FGF23 and impaired innate immunity in CKD. As detailed above, CKD is a state of acquired immune deficiency involving both cellular and humoral immunity,27 and circulating levels LL37 in this population appear to be an independent risk factor of mortality by infections.58 In a similar fashion, higher quartiles of serum FGF23 are associated with an increased risk of mortality across the spectrum of CKD,23, 59 and non-CKD populations,60 mainly in terms of cardiovascular mortality; therapy with vitamin D sterols is associated with reduced mortality in dialysis patients.55, 56 Prospective randomized trials will be required to define the role of FGF23 on overall patient survival as well as the impact of therapy with vitamin D. Although therapeutic targeting of FGF23 may be a strategy to delay the onset of secondary hyperparathyroidism and bone and mineral disorders associated with CKD, the effects of such an approach on global and cardiovascular morbimortality have yet to be studied. However, based on data presented here, we propose that therapies aimed at lowering circulating levels of FGF23 may have immediate benefits for the morbimortality induced by infections in the CKD population.

To date, studies of vitamin D-induced innate immunity have focused exclusively on monocytes derived from PBMCs.12, 13 Stubbs and colleagues61 demonstrated modulation of vitamin D-dependent biomarkers in PBMC following native oral vitamin D supplementation in hemodialysis patients, but without any evaluation of a potential interplay between vitamin D and FGF23 pathways. However, in CKD it seems more likely that antibacterial activity will arise from tissue-localized monocytes and macrophages rather than from the circulating populations of these cells. With this in mind, a key objective of the current study was to characterize the vitamin D system and vitamin D-induced immunity in a population of cells more closely associated with infection in CKD patients, namely PDm. Previous studies have shown that peritoneal macrophages from dialysis patients are able to synthesize 1,25(OH)2D,62 but the relevance of this finding to innate immunity remains unclear. PDm and PBMCm express similar levels of CYP27B1, but the relatively high levels of FGFR1/Klotho in PDm may facilitate FGF23 suppression of CYP27B1 in these cells. Despite this, FGF23 treatment did not significantly suppress LL37 expression in PDm. One explanation for this is that baseline levels of LL37 are lower in PDm relative to PBMC, and may thus be resistant to further suppression. Conversely, baseline expression of CYP24A1 is significantly higher in PDm relative to PBMCm and this is also likely to influence intracrine responses to 25D in these cells.

In future studies, it will be interesting to characterize further the difference between PDm and PBMCm with respect to vitamin D-mediate immune function. For the current study it was not possible to obtain sufficient blood from the pediatric CKD donors of the PD cells to enable parallel isolation of PBMCm. However, direct comparison between these two populations of monocytes may provide important new insights on the immunomodulatory effects of vitamin D in vivo. Future studies will also need to further clarify the wider impact of FGF23 on immune function. The current study focuses on the intracrine effects of vitamin D on monocyte function but it is also possible that FGF23 will act to suppress CYP27B1 in other immune cells that express this enzyme, such as DCs.33, 34 In this way, FGF23 may not only influence innate antibacterial responses to infection but it may also affect antigen presentation by DCs and concomitant adaptive T cell/B cell immune activity. This may be particularly important in CKD patients in whom inflammation is a key feature of disease pathophysiology, with reported links to patient vitamin D status.63 Effects of FGF23 on DC vitamin D metabolism and antigen presentation may also impact on adaptive immune response to kidney transplantation. Recent studies from our group have highlighted association between FGF23 levels, deteriorating kidney function and host-graft rejection in pediatric CKD transplantation patients.64 The role of immune vitamin D metabolism in this setting has yet to be studied but may provide an important mechanism for future therapeutic intervention to improve transplantation success.


All authors state that they have no conflicts of interest.


This work was supported in part by educational grants (AcadémieFrançaise/Jean Walter Zellidja, RéunionPédiatrique de la Région Rhône Alpes, SociétéFrançaise de Pédiatrie/Evian, Fondation pour la RechercheMédicale, Philippe Foundation, to JB), by a grant from the Center for D-receptor Activation Research (CeDAR, to MH), by NIH grant DK0911672 (to MH), by USPHS grants DK 67563, DK 35423, DK 80984, and funds from the Casey Lee Ball Foundation (to IBS and KWP).We thank Deborah Krakow, MD, Anna Sarukhanov, and Margarita Ivanova (UCLA) for their help with the Western blot analyses.

Authors' roles: JB performed the experiments as well as the statistical analyses, and wrote the manuscript; JLS, RFC, and TSL did some of the experimental work; KWP and IBS helped to design the study and to analyze the results; JSA helped to analyze data; BG was involved in patient recruitment; MH initially designed the study, helped to analyze the results, and edited the manuscript.